4.7 Review

Nab-Paclitaxel in the Treatment of Gastrointestinal Cancers-Improvements in Clinical Efficacy and Safety

Journal

BIOMEDICINES
Volume 11, Issue 7, Pages -

Publisher

MDPI
DOI: 10.3390/biomedicines11072000

Keywords

nab-paclitaxel; paclitaxel; efficacy; safety; toxicity; overall response rate (ORR); overall survival (OS); progression-free survival (PFS)

Ask authors/readers for more resources

Taxanes, such as paclitaxel and docetaxel, are effective anticancer drugs but have high hydrophobicity and toxicity. Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) is a novel formulation that improves solubility, reduces toxicity, and allows higher doses and concentrations compared to solvent-based paclitaxel. It has been approved for metastatic breast cancer, NSCLC, and pancreatic adenocarcinoma. Clinical trials have also shown its potential efficacy in other gastrointestinal cancers. This review summarizes the advantages of nab-paclitaxel-based regimens in terms of improving clinical efficacy and safety profile in upper gastrointestinal cancer.
Taxanes (paclitaxel and docetaxel) are one of the most useful classes of anticancer drugs. Taxanes are highly hydrophobic; therefore, these drugs must be dissolved in organic solvents (polysorbate or Cremophor EL), which contribute to their toxicities. To reduce this toxicity and to enhance their efficacy, novel formulations have been developed. Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) is an albumin-stabilized, Cremophor-free, and water-soluble nanoparticle formulation of paclitaxel. Nab-paclitaxel has better solubility and less infusion-associated toxicity compared to solvent-based paclitaxel. Additionally, nab-paclitaxel can be given at higher doses and concentrations compared with solvent-based paclitaxel. Based on its superior clinical efficacy and safety profile, nab-paclitaxel received FDA approval for metastatic breast cancer (2008) and NSCLC (2011). Among gastrointestinal cancers, it is now approved in the USA for treating patients with metastatic adenocarcinoma of the pancreas as first-line therapy in combination with gemcitabine. Furthermore, several clinical trials have suggested the potential efficacy of nab-paclitaxel as a single agent or in combination with other agents for the treatment of metastatic esophageal, gastric, bowel, and biliary tract cancers. Nab-paclitaxel has been demonstrated to have greater overall response rates (ORR) with enhanced progression-free survival (PFS), overall survival (OS) and a superior safety profile with fewer adverse effects in patients with gastrointestinal tract cancers. This review summarizes the advantages associated with nab-paclitaxel-based regimens in terms of improving clinical efficacy and the safety profile in upper gastrointestinal cancer.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available